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Purpose. The oral bioavailability of some therapeutic agents is markedly lower 
in cynomolgus monkeys than in humans. We investigated small-intestinal 
absorption of the P-glycoprotein (P-gp) substrates etoposide and digoxin in 
monkeys to clarify the influence of efflux transport on their intestinal permeability.  
Methods. The pharmacokinetics of etoposide and digoxin was examined in 
monkeys and rats after oral and intravenous administration. Intestinal 
permeability and segmental differences in permeability were investigated with an 
Ussing-type chamber. 
Results. The bioavailability of etoposide was 12.9 and 13.9% in monkeys and 
rats, respectively. Total body clearance of etoposide in monkeys was much less 
than hepatic blood flow, suggesting that the bioavailability would be limited at 
intestinal absorption. Marked vectorial transport of etoposide in the secretory 
direction was observed in rats, especially in the lower small intestine, and 
segmental differences were consistent with the distribution of P-gp expression. 
Vectorial transport was minimal in monkey small intestine. Our kinetic analysis 
indicated that P-gp contributes little to the intestinal permeability of etoposide 
and digoxin in monkeys, and apical uptake is rate-limiting. 
Conclusion. Low bioavailability of etoposide in monkeys is due to poor intestinal 





Absolute oral bioavailability is an important determinant of the 
pharmacological efficacy of orally administered drugs. However, it is difficult to 
predict oral bioavailability in humans from preclinical studies, even using 
non-human primates. For example, cynomolgus monkeys are sometimes used 
in preclinical studies, but they tend to exhibit lower bioavailability than humans 
(1-3). In extreme cases, this may result in inappropriate termination of drug 
development. It is therefore important to understand in detail the processes 
involved in small intestinal absorption in monkeys. 
Recently, we investigated the oral bioavailability and intestinal 
absorption mechanism of midazolam, a typical substrate of CYP3A, in both 
monkeys and rats. While the oral bioavailability of midazolam was poor in both 
species, the intestinal availability of midazolam was poor only in monkeys (4). 
We found that potent metabolic activity for midazolam was asymmetrically 
localized inside the small-intestinal cells in monkey, suggesting that midazolam 
would be rapidly and extensively metabolized after having been taken up across 
the apical membrane (4). However, it remains to be addressed whether poor 
bioavailability of other drugs in monkeys can be similarly explained, since 
penetration of xenobiotics across the small intestine is influenced at least two 
factors, i.e., CYP3A and P-gp, the substrate specificities of which partially 
overlap (5, 6). Accordingly, the species difference of bioavailability of at least 
some drugs might not be due to a difference in intestinal metabolism, but rather 
to a difference of efflux transport across small intestinal epithelial cells.  
 Several efflux pumps, such as P-gp, multidrug resistance-associated 
protein 2 (ABCC2) and breast cancer resistance protein (ABCG2), are 
expressed on the apical membrane of intestinal epithelial cells, and are involved 
in efflux of substrates from inside the cells into the intestinal lumen (7-10). P-gp 
is a well-known efflux pump that limits the intestinal penetration of many 
xenobiotics, including various drugs (11, 12). However, little is known about the 
contribution of these efflux transporters to intestinal drug absorption in 
cynomolgus monkeys.  
To address whether the lower oral bioavailability depends on 
membrane permeability in the small intestinal tissues, it is necessary to study the 
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intestinal absorption mechanism using a model drug that shows poor 
bioavailability in monkeys. In the present study, we selected two test compounds 
(etoposide and digoxin) to assess the involvement of P-gp in intestinal 
absorption in monkeys, based on the following criteria: a) substrates of P-gp, b) 
sufficient oral bioavailability at least in humans, c) poor metabolic clearance with 
oral bioavailability being primarily determined by the intestinal first-pass removal. 
Etoposide, a topoisomerase II inhibitor, is a P-gp substrate, and its intestinal 
absorption is regulated by P-gp (13, 14). Plasma clearance of etoposide is 0.68 
(mL/min/kg), and its oral bioavailability is 52% in humans (15). Therefore, 
etoposide should be a suitable probe for studying the effect of P-gp on intestinal 
drug absorption, since its membrane permeability in the small intestine directly 
affects its oral bioavailability. Digoxin, another typical substrate of P-gp, was also 
used in the present study to analyze the influence of P-gp on intestinal 
absorption in monkeys, since hepatic first-pass removal of digoxin is not large. 
With these drugs, the bioavailabilities of which are primarily determined by the 
small intestinal permeability, we expected that it would be possible to assess the 
contributions of apical uptake and efflux processes in the small intestine to the 
overall bioavailability. For comparison, we also investigated theophylline, which 
is rapidly absorbed with minimal first-pass metabolism, and is poorly transported 
by P-gp. 
In the present study, we used an Ussing-type chamber system, since 
its advantages as an experimental system for analyzing intestinal drug transport 
include easy assessment of vectorial transport across intestinal tissues, and the 
ability to determine kinetic parameters of permeation across the apical and basal 
sides, so that the rate-limiting process in the overall intestinal permeability can 




Materials and Methods 
Chemicals. 
Etoposide, digoxin and FD-4 were purchased from Sigma (St. Louis, MO). 
Theophylline was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, 
Japan). [3H]Digoxin (0.33 TBq/mmol) was purchased from PerkinElmer Life and 
Analytical Sciences (Boston, MA). [14C]Inulin (161 MBq/g) was purchased from 
ICN Biomedicals, Inc. (Costa Mesa, CA). C219 monoclonal antibody (Dako, 
Carpinteria, CA) and anti-mouse IgG (Amersham Biosciences, Buckinghamshire, 




Cynomolgus monkeys (5-6 years old, male) were purchased from China 
National Scientific Instruments & Materials Import / Export Corporation (China), 
and maintained on approximately 108 g of food (Teklad Global 25% Protein 
Primate Diet, Harlan Teklad, Madison, WI) once a day, with free access to water. 
Sprague-Dawley rats (7 weeks old, male) were purchased from Japan SLC 
(Hamamatsu, Japan) and maintained with free access to food and water. 
Animals were deprived of food for one day before experiments. Animal studies 
were performed in accordance with the Guidelines for the Care and Use of 
Laboratory Animals, Kanazawa University. 
 
Pharmacokinetic properties of etoposide, digoxin and theophylline in 
monkeys and rats 
Etoposide, digoxin and theophylline were each dissolved in a mixture of 
dimethylacetamide and saline (1:1, v/v) for intravenous bolus injection at a dose 
of 0.1 mg/0.2 mL/kg for monkeys and 0.1 mg/mL/kg for rats. Intravenous bolus 
injection was conducted without cannulation into the saphenous vein in monkeys 
and into the femoral vein in rats. Etoposide and theophylline were suspended in 
0.5% methylcellulose solution for oral administration at a dose of 1 mg/2 mL/kg 
for monkeys and 1 mg/5 mL/kg for rats. Digoxin was suspended in 0.5% 
methylcellulose solution for oral administration at a dose of 0.3 mg/2 mL/kg for 
monkeys. Oral administration to rats was done by gavage. Blood samples were 
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collected at 5, 10, 15, and 30 min, and 1, 2, 4, 8, and 24 hr after intravenous 
administration and at 15 and 30 min, and 1, 2, 4, 8, and 24 hr after oral 
administration in monkeys and rats. 
 
Transport experiment and measurement of radioactivity in Ussing-type 
chamber 
The apparatus and the method for the preparation of monkey and rat small 
intestinal tissue were described previously (4). Briefly, segments of upper, 
middle and lower small intestine isolated from monkeys and rats were used for 
the Ussing-type chamber study. Isolated intestinal tissue sheets from which the 
muscle layer had been removed with fine tweezers were mounted vertically in 
Ussing-type chambers that provided an exposed area of 0.75 cm2 for monkeys 
and 0.25 cm2 for rats. The volume of bathing solution on each side was 1.2 mL, 
and the solution temperature was maintained at 37 °C in a water-jacketed 
reservoir. The test solution was composed of (mM): 128 NaCl, 5.1 KCl, 1.4 CaCl2, 
1.3 MgSO4, 21 NaHCO3, 1.3 KH2PO4, 10 NaH2PO4 and 5 D-glucose (adjusted to 
pH 6.0 or 7.4 for the apical (AP) or basal (BL) side, respectively), and gassed 
with 95% O2/5% CO2 before and during the transport experiment. The etoposide 
or digoxin concentration on the donor side was set to be 30 µM and the 
theophylline concentration was set to be 300 µM. At 5, 30, 60, 90 and 120 min, a 
250-µL aliquot of acceptor-side buffer was sampled and replaced with an equal 
volume of fresh buffer. The experiment was continued for 120 min, after which 
time the tissue and buffer on the donor side were also collected. [3H]Digoxin in 
250-µL aliquots of the apical and basal side buffer solution from the rat 
Ussing-type chamber was directly mixed with 3 mL of scintillation cocktail 
(Clearsol-I, Nacalai tesque, Kyoto, Japan). Rat intestinal tissue homogenates 
were solubilized with 1 mL of Soluene 350 (Packard BioScience B.V., Groningen, 
Netherlands) for 3-4 hr at 55 °C, and then 100 µL of H2O2 was added and 
neutralized with 100 µL of 5 N HCl. Radioactivity was measured with a liquid 
scintillation counter (LSC-5100, Aloka Co., Ltd., Tokyo, Japan). 
 
Serum protein binding of etoposide 
The free fraction of etoposide in serum was determined in vitro by equilibrium 
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dialysis methods using 96-well Equilibrium DIALYZER (molecular weight cut-off 
of 10 kDa, Harvard Bioscience, Holliston, MA). Etoposide was added to monkey 
and rat serum at a concentration of 1 µM.  Phosphate-buffered saline (PBS) 
was used as dialysis buffer. Dialysis was conducted in quadruplicate for 20 hr at 
room temperature. Concentrations of compounds in dialysate were analyzed by 
LC/MS/MS.     
 
Measurement of drug concentration by means of high-performance liquid 
chromatography with tandem mass spectrometry (LC/MS/MS)  
Etoposide, digoxin or theophylline in 100-µL aliquots of plasma, the apical-side 
and basal-side buffers from the Ussing-type chamber, and tissue homogenates 
were extracted with 10 µL of acetonitrile and 100 µL of internal standard solution 
(100 ng/mL alprenolol, 50 ng/mL lanatoside C or 100 ng/mL phenytoin, 
respectively, in acetonitrile). The mixtures were centrifuged at 3,000 rpm to 
remove precipitated protein. For etoposide, 100 µL of supernatant was then 
diluted with 200 µL of 0.01 M ammonium formate (pH 3.0). A 20-µL aliquot was 
analyzed by means of LC/MS/MS. The flow rate was set at 0.2 mL/min. 
Separation was performed at 40 °C with a gradient system generated from 0.01 
M ammonium formate, pH 3.0 (A) and 0.2% formic acid in acetonitrile (B): B was 
held at 10% for 1 min, increased linearly to 90% in 1 min, held at 90% for another 
2.5 min, and then brought back to 10% in 0.1 min, followed by re-equilibration for 
2.9 min.  
For determination of digoxin in rat plasma, 100 µL of supernatant was diluted 
with 100 µL of 0.01 M ammonium formate (pH 3.0). For digoxin in monkey 
plasma, 150 µL of supernatant was evaporated and the residue was suspended 
in 50 µL of a mixture of 0.01 M ammonium formate and acetonitrile (3:1). Each 
solution was centrifuged at 15,000 rpm for 5 min. For digoxin in monkey 
intestinal tissue, 150 µL of supernatant was diluted with an equivalent volume of 
0.01 M ammonium acetate. A 20-µL aliquot was then analyzed by means of 
LC/MS/MS. The flow rate was set at 0.2 mL/min, and the eluent consisted of 
0.02 M ammonium formate (0.02 mL/min) and the following gradient system 
(0.18 mL/min). Separation was performed at 40 °C with the gradient system 
generated from distilled water (A) and acetonitrile (B): B was held at 15% for 1 
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min, increased linearly to 90% in 1.5 min, held at 90% for another 2 min, and 
then brought back to 15% in 0.1 min, followed by re-equilibration for 1.9 min. For 
determination of theophylline, 100 µL of supernatant was diluted with 200 µL of 
0.01 M ammonium formate (pH 3.0). A 20-µL aliquot was taken and analyzed by 
means of LC/MS/MS. The flow rate was set at 0.2 mL/min. Separation was 
performed at 40 °C with a gradient system generated from 0.01 M ammonium 
formate, pH 3.0 (A) and methanol (B): B was held at 15% for 0.75 min, increased 
linearly to 90% in 0.25 min, held at 90% for another 4.5 min, and then brought 
back to 10% in 0.1 min, followed by re-equilibration for 3.4 min. The LC system 
was a Shimadzu series SIL-10AHc (Shimadzu, Kyoto, Japan). The analytical 
column was a CAPCELL PAK C18 MGII (2.0 x 20 mm for etoposide and digoxin), 
and CAPCELLPAK C8 (2.0 x 150 mm for theophylline) column (Shiseido, Tokyo, 
Japan). Mass spectrometry experiments were conducted on a PE-Sciex 
API-3000 or API-4000 instrument (Applied Biosystems, Foster City, CA) with 
positive (for etoposide and digoxin) or negative (for theophylline) ionization 
electrospray. The multiple reaction monitor was set at 589.1 to 229.0, 249.9 to 
116.3, 798.7 to 651.2, 1002.5 to 651.2, 179.0 to 163.9 and 250.8 to 101.8 m/z 
for etoposide, alprenolol, digoxin, lanatoside C, theophylline and phenytoin, 
respectively. 
 
Western blot analysis 
The tissue preparation of monkey and rat intestinal mucosa was described 
previously (4). All samples were diluted to equal protein concentration (4.4 mg 
protein/mL), and then 43.4 mM Tris-HCl, pH 6.8, 1% SDS, 5% 
ß-mercaptoethanol (final concentrations) and urea were added. Proteins (20 
µg/lane) were separated by SDS-PAGE (10% polyacrylamide gel), and 
transferred onto a polyvinylidene difluoride membrane (Millipore Corporation, 
Billerica, MA) at 2 mA/cm2 for 120 min. Ponceau S staining confirmed that each 
lane was equally well transferred to the membrane (data not shown). For 
detection of monkey P-gp protein, the membrane was incubated in Tris-buffered 
saline (20 mM Tris-HCl, pH 7.5 and 137 mM NaCl, 0.1% Tween 20) containing 
5% skim milk for blocking, and then incubated with 1% C219 monoclonal 
antibody (DAKO) in the above buffer containing 0.5% skim milk. The 
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membranes were rinsed with Tris-buffered saline containing 0.1% Tween 20, 
and reacted with 0.05% horseradish peroxidase-conjugated donkey anti-mouse 
IgG as the secondary antibody (GE Healthcare). Bands were visualized by using 
the enhanced chemiluminescence detection method with the ECL Plus Western 
blotting detection system (GE Healthcare). Quantitative analysis was done by 




Transport clearances in the Ussing-type chamber were estimated by means of 
the following equations: 





       (1) 





       (2) 
where CLabs, Xbasal and AUCapical mean transport clearance in the AP-to-BL 
direction, the amount of parent drug that appeared in the BL compartment, and 
the area under the parent drug concentration curve in the AP compartment, 
respectively, while CLsec, Xapical and AUCbasal are the corresponding parameters in 
the opposite direction. Both CLabs and CLsec were measured by assuming that 
drug concentration in the tissue and drug appearance in the acceptor side 
reached at the steady-state. Membrane permeability was analyzed was 
calculated by use of the following equations: 
! 
CLabs = CLAT "
CLTB
CLTA+ CLTB
      (3) 
! 
CLsec = CLBT "
CLTA
CLTA+ CLTB
      (4) 
CLAT is defined as the membrane permeability across the apical membrane from 
outside of the tissue to inside of the tissue (apical-to-tissue). Similarly, CLTA, CLTB 
and CLBT represent the tissue-to-apical, tissue-to-basal, and basal-to-tissue 
membrane permeabilities, respectively.  
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If we assume a steady-state condition for the amount of parent drug in 
tissue and a sink condition for the acceptor, the influx rate from the donor-side 
chamber into tissue is equal to the elimination rate from tissue. 
For AP-to-BL transport, 
! 
CLAT "Capical = (CLTA+ CLTB) "Ctissue, a # b     (5) 
For BL-to-AP transport, 
! 
CLTB"Cbasal = (CLTA+ CLTB) "Ctissue, b # a     (6) 
where Ctissue,a-b and Ctissue,b-a are the parent drug concentration in small intestinal 
tissue, calculated on the assumption that specific gravity of the tissue is unity, at 
the end of the experiment after drug addition to the apical-side and basal-side 
chambers, respectively. Therefore, all the microscopic parameters (CLAT ~ CLBT) 
can be directly calculated by use of the following equations: 
! 
CLAT = CLabs" (CLTA+ CLTB) /CLTB     (7) 
! 
CLTA = CLsec /(Ctissue, b " a /Cbasal)      (8) 
! 
CLTB = CLabs /(Ctissue, a " b /Capical)      (9) 
! 
CLBT = CLsec" (CLTA+ CLTB) /CLTA     (10) 
 
Statistical Analysis 
Plasma concentrations of drugs and pharmacokinetic parameters in vivo are 
presented as mean ± standard deviation (S.D.). Other data are presented as 
mean ± standard error of the mean (S.E.M.). Statistical comparisons were 
performed by means of Student’s t-test or ANOVA with Tukey’s post hoc 
comparison test. Values of p < 0.05 were considered to be significant. 





Oral absorption of model drugs in vivo 
 To evaluate the disposition of etoposide, digoxin and theophylline in 
monkeys, we measured pharmacokinetic parameters after intravenous and oral 
dosing (Fig. 1 and Table 1). Theophylline was almost completely absorbed with 
90-100% bioavailability ( B.A.) in monkeys and rats (Table 1), demonstrating that 
first-pass metabolism is minimal. Oral absorption of theophylline was rapid, and 
similar MRT values were obtained after intravenous and oral dosing (Table 1). 
The total clearance (CLtotal) of etoposide in monkeys and rats was smaller than 
the hepatic blood flow (2616 and 2832 mL/h/kg in monkey and rat, 
respectively)(16)(Table 1). Even when the blood-to-plasma concentration ratio 
for etoposide (0.7 and 1.0 in monkey and rat, respectively) is taken into 
consideration, blood clearance was lower than the hepatic blood flow, 
suggesting that hepatic first-pass extraction is minor (~0.05) in monkey and 
moderate (~0.55) in rat, and intestinal availability primarily limits oral 
bioavailability in both species. Digoxin also showed little hepatic first-pass effect, 
and the oral bioavailablity appears to be determined by the intestinal permeation, 
since the blood clearance is sufficiently lower than the hepatic blood flow (Table 
1). The bioavailability of etoposide and digoxin in monkeys (10~20%, Table 1) is 
much lower than that in humans (52% and 70%, respectively)(15). One of the 
possible explanations is that species differences exist in the intestinal 
permeability of these drugs, although we cannot exclude the other possibility that 
the formulation of them would affect the oral bioavailability, as suggested by 
Shah et al. for the absorption of etoposide in rats (17). Although the values of 
distribution volume (Vd(ss)) of digoxin and theophylline were similar between 
monkeys and rats, that of etoposide was lower in monkeys than in rats (Table 1). 
This may be because of species difference in plasma protein binding (the 
plasma free fraction of etoposide was estimated to be 0.02 and 0.23 in monkeys 
and rats, respectively). 
 
Transport of etoposide, digoxin and theophylline across upper, middle 
and lower small intestine of monkeys and rats 
 To evaluate the intestinal availability of etoposide in monkeys, the 
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intestinal permeability of etoposide, digoxin (or [3H]digoxin) and theophylline was 
measured in an Ussing-type chamber. Permeability of FD-4 (or [14C]inulin) as a 
slowly absorbed marker drug was also evaluated. To avoid nonlinear transport 
and cellular toxicity, the concentration of etoposide or digoxin in the donor-side 
chamber was set as low as possible, consistent with obtaining a detectable level 
in the acceptor-side chamber. Since the major intestinal site for the absorption of 
etoposide was not known, we divided the small intestine into three segments 
(upper, middle and lower parts). The permeability of each segment in the 
AP-to-BL and BL-to-AP directions was measured, and transport clearances of 
each compound were calculated by using Eq(1) and (2), as shown in Fig. 2. No 
efflux transport of etoposide or digoxin was observed in monkeys, whereas clear 
efflux (CLsec > CLabs) of etoposide and digoxin was observed in all the segments 
and lower segment of rat small intestine, respectively (Fig. 2), suggesting that 
the intestinal P-gp function in monkeys is less active than in rats. In contrast to 
theophylline, the permeability of which was much higher than that of FD-4 in all 
segments of both monkeys and rats (Fig. 2), the AP-to-BL transport of etoposide 
or digoxin was close to that of FD-4 in monkeys and rats (Fig. 2). These results 
indicate that the limited bioavailability of etoposide in monkeys and rats is a 
consequence of smaller intestinal permeability. In monkeys, the permeability of 
FD-4 was slightly higher in the lower part than the upper and middle parts (Fig. 
2A). Although the reason for this result is unknown, this may be relevant to the 
similar regional difference for the permeability of etoposide and digoxin (Fig. 2A).  
 
Intestinal absorption mechanism assessed by model analysis 
To understand in detail the intestinal absorption mechanism of 
etoposide, permeability across the apical and basolateral membranes was 
separately estimated based on the Ussing-type chamber data, assuming a 
steady-state condition. The parameters obtained are listed in Table 2. Note that 
not all the data are directly comparable. Comparison between CLTA and CLTB and 
that between CLAT and CLBT are reasonable since both parameters are intrinsic 
clearances based on drug concentration in the donor side of chamber, where all 
the drug molecules are assumed to be in unbound (free) form. On the other hand, 






respectively, where ft, CLTAf and CLTBf are the free fraction in tissue, the intrinsic 
apical efflux clearance from tissue and the intrinsic basal efflux clearance from 
tissue, respectively. We evaluated CLTA and CLTB instead of CLTAf and CLTBf, 
since we could not determine ft for technical reasons. Therefore, direct 
comparison between CLAT and CLTA is not appropriate. In the case of 
comparison of membrane permeability between drugs or animal species, direct 
comparison of CLAT or CLBT is reasonable, but comparison between CLTA or CLTB 
may not be acceptable since ft values are variable from compound to compound.  
CLAT of etoposide in monkey small intestine was markedly lower than 
that in rats, whereas CLAT of theophylline was similar in monkeys and rats (Table 
2). Regional difference of CLAT of etoposide was at most 2-fold in monkey small 
intestine, whereas CLAT of etoposide in rat lower small intestine was 
approximately 6-fold higher than that in the upper small intestine (Table 2). In 
monkey upper and middle small intestine, CLTA of etoposide was much lower 
than CLTB, whereas the difference between CLTA and CLTB of theophylline was at 
most 2-fold (Table 2). Consequently, the CLabs values of etoposide were close to 
CLAT (Fig. 2, Table 2), indicating that apical uptake of etoposide is the 
rate-limiting step of intestinal absorption in monkeys. Similar results were also 
obtained for digoxin, although significant difference between CLTA and CLTB was 
obtained only in monkey lower intestine. However, in rat small intestine, 
especially in the lower segment, the values of CLTA of etoposide and digoxin 
were higher than CLTB, whereas CLTA of theophylline was similar to CLTB (Table 
2). These results indicate that once etoposide and digoxin are taken up by 
intestinal tissues across the apical membrane in rats, they are mostly excreted 
back into the intestinal lumen, whereas theophylline taken up across the apical 
membrane is distributed almost equally to the apical and basal membrane sides. 
The values of CLTA of etoposide and digoxin in rats gradually increased from the 
upper to the lower small intestine, and this is consistent with the reported 
regional differences of P-gp function and expression (14, 18). 
 
P-gp expression in monkey and rat small intestines 
 To assess the P-gp function in monkey small intestine, we measured 
P-gp expression in monkey and rat small intestines by Western blot analysis. 
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Specific bands for P-gp was detected at around 170 kDa (Fig. 3). Monkey small 
intestine exhibited little regional difference, whereas expression in rat lower 
intestine tended to be higher than that in rat upper one, although there was no 
statistical significance (Fig. 3).  
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Discussion 
Monkeys tend to exhibit lower oral drug bioavailability than humans (1, 
2). Indeed, we observed extensive metabolism of midazolam, a typical substrate 
of CYP3A, in small intestine of monkeys, and suggested that difference of 
intestinal metabolism might be the key to the species difference in the oral 
bioavailability of midazolam (4). However, oral bioavailability is influenced by 
membrane permeability (e.g., P-gp activity), as well as intracellular metabolism 
(e.g., CYP3A activity) and other factors (5, 6). In the present study, CLtotal of 
etoposide was low and close to that of theophylline, the bioavailability of which is 
close to unity in monkeys (Table 1), indicating that there is a negligible hepatic 
first-pass effect in the case of etoposide. Nevertheless, the oral bioavailability of 
etoposide in monkeys (Table 1) was much lower than that in humans (~52%, 15). 
Therefore, we hypothesized that intestinal absorption of etoposide in monkeys 
was less than in humans. 
To investigate the intestinal absorption mechanism of etoposide, we 
utilized an Ussing-type chamber system and measured AP-to-BL and BL-to-AP 
transport of etoposide, as well as several reference compounds, i.e., digoxin, 
another P-gp substrate, theophylline, a rapidly absorbed and poorly 
first-pass-metabolized marker, and FD-4 (or [3H]inulin), a slow absorption marker, 
in the upper, middle and lower small intestine of monkey and rat. Intestinal 
permeability (CLabs) of etoposide and digoxin in both species was similar to that 
of FD-4 (or [3H]inulin), suggesting that the permeability of both compounds would 
be low (Fig. 2). On the other hand, the extent of oral bioavailability of etoposide 
and digoxin in rats were 13.9% and 52.8%, respectively (Table 1), being much 
greater than the fraction absorbed of inulin in rats (~3.5% of dose), as estimated 
from the urinary excretion of inulin after oral administration (19). These results 
indicate that it is difficult to predict the in vivo fraction absorbed from intestinal 
permeability data, even if freshly isolated intestinal tissue is available. One of the 
possible explanations would be the difference in concentration gradient between 
luminal and blood sides in vivo which was not considered in the present study, 
but may drive greater mass across the intestine, affecting oral bioavailability. In 
rats, however, CLsec of etoposide and digoxin was higher than CLabs in the lower 
small intestine (Fig. 2), and this is consistent with findings by other groups (14, 
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20). Vectorial transport across the small intestine, which is thought to reflect the 
contribution of efflux transporter(s), is usually evaluated in terms of the efflux 
ratio (CLsec/CLabs). Values of efflux ratio of etoposide and digoxin in monkey 
intestine were much lower than that in rat intestine (Fig. 2), suggesting that there 
is a difference in the contribution of efflux transporter(s) (possibly P-gp) between 
monkeys and rats. 
The Ussing-type chamber system is useful technique to separately 
estimate microscopic parameters representing permeability across basal and 
apical membranes. However, this system needs appropriate control studies 
using both rapid and slow absorption markers (theophylline and FD-4 or inulin, 
respectively, in the current study). Both FD-4 and inulin are often used as 
paracellular markers, and the permeability of these compounds could actually 
include the permeability through the paracellular route. Nevertheless, as shown 
in Fig. 2, the permeability of FD-4 was higher than that of etoposide and digoxin 
in monkey duodenum (Fig. 2). This cannot be explained even if we consider that 
FD-4 is the paracellular marker, and permeability of FD-4 may not adequately 
represent the paracellular route of etoposide or digoxin. Therefore, those slow 
absorption markers were used in the current study to simply evaluate 
experimental technique and variability in Ussing-type chamber studies. On the 
other hand, permeability of FD-4 or inulin was close to that of etoposide and 
digoxin with the exception of secretory directions in rat middle and lower 
intestines (Fig. 2), indicating slow permeation of etoposide and digoxin. However, 
we measured the amount of etoposide, digoxin and inulin associated with the 
tissues in rats at the end of the chamber experiments, and the tissue-associated 
amount of etoposide in monkeys and rats, and that of etoposide in rats were 
much higher than that of inulin (data not shown), suggesting that etoposide and 
digoxin could be accumulated inside the tissues other than the paracellular 
space, and subjected, at least partly, to the transcellular permeation. Therefore, 
in the present study, we estimated microscopic parameters to compare the 
membrane permeability with each other (Table 2). 
Trountman et al. suggested that efflux ratio is not an appropriate 
indicator for assessing the influence of P-gp on CLabs (21). In the present study, 
we quantitatively analyzed the permeability of each intestinal membrane with the 
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use of a simple kinetic model to understand in more detail the species difference 
in the intestinal transport (Fig. 4). CLTA of etoposide was much higher than CLTB 
in rat small intestine, indicating that intestinal absorption of etoposide was limited 
by P-gp function in rats (Table 2, Fig. 4), which is consistent with previous 
findings by other groups. On the contrary, apical uptake clearance (CLAT) of 
etoposide in monkey small intestine was markedly lower than that of theophylline 
and was close to CLabs (Fig. 2, Table 2), indicating that apical uptake is the 
rate-limiting process of intestinal etoposide absorption in monkey (Fig. 4). It 
should also be noted that CLabs of etoposide and digoxin was close to that of 
FD-4 especially in monkeys (Fig. 2). This indicates smaller membrane 
permeability in monkeys, compared with rats, but the contribution of paracellular 
route to the overall intestinal permeability should also be considered.  
CLAT of etoposide in rat small intestine was higher than that in monkeys, 
although CLAT of theophylline was similar in monkeys and rats (Table 2), 
implying that an active transport system(s) is involved in intestinal uptake of 
etoposide, at least in rats. This would be consistent with previous reports that the 
oral AUC of etoposide was saturated with increasing dose, and was decreased 
by grapefruit juice intake (22-24). Moreover, according to Lipinski’s “rule-of-5” or 
the prediction method based on the value of polar surface area (12, 25, 26), poor 
absorption of etoposide can be expected owing to its physicochemical 
characteristics (12). However, etoposide exhibits higher bioavailability in 
humans (> 50% of dose after oral administration) than in laboratory animals. 
Therefore, it is possible that species difference of intestinal absorption of 
etoposide is associated with a transport system(s) that is functionally expressed 
in humans and rats, but poorly expressed in monkeys. Values of CLTA of 
etoposide and digoxin in the lower small intestine of monkey and rat were higher 
that those in the upper segment of the small intestine (Table 2). This is 
compatible with the regional difference in P-gp expression in rats (Fig. 3), but 
such a regional difference in P-gp expression was not observed in monkeys (Fig. 
3). These results indicate that the regional difference of CLTA cannot be fully 
explained by P-gp, and another efflux transporter(s) and/or intracellular binding 
may be influence intestinal efflux in monkeys.  
 We also measured the intestinal permeability of etoposide and digoxin 
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at higher concentrations (300 µM etoposide and 250 µM digoxin) than 30 µM in 
rat upper, middle and lower small intestine. In the lower small intestine, CLabs of 
digoxin examined at 250 µM (3.35 ± 0.75 
! 
"10-6 cm/sec) was higher than that at 
30 µM (Fig. 2), whereas little difference was seen in the case of etoposide. 
Therefore, P-gp may be more easily saturated with digoxin than with etoposide, 
i.e., saturation of P-gp favors digoxin absorption in rats. Moreover, it has been 
suggested that an influx transporter is involved in digoxin absorption (27). 
Organic anion transporting polypeptide 2 (Oatp2, Slco1a3), which can transport 
digoxin, is expressed in the small intestine, at least at the mRNA level (28, 29). 
However, its human ortholog OATP-A (SLCO1A2), which is also expressed in 
the small intestine, does not transport digoxin (30, 31). In monkeys, on the other 
hand, we have only measured the intestinal permeability of etoposide and 
digoxin at 30 µM due to the detection limit. Therefore, we cannot conclude any 
possible saturation in the influx and/or efflux transport systems in monkeys. 
Further studies are necessary to clarify all the factors affecting absorption of 
digoxin and etoposide. 
 In addition to P-gp, MRP2 (ABCC2) and BCRP (ABCG2) are also 
expressed on apical membranes of small intestinal epithelial cells (7-9). 
Although etoposide is a substrate of both of them (32, 33), P-gp mainly regulates 
its intestinal absorption in mice (13), and this is consistent with our present 
finding that P-gp is involved in the intestinal absorption of etoposide in rats (Figs. 
2, 3). In contrast to rodents, monkeys showed little involvement of P-gp in 
intestinal permeation of etoposide or digoxin (Fig. 2, Table 2), although P-gp 
expression was detected in all segments of the small intestine (Fig. 3), and the 
P-gp-mediated etoposide transport seemed to be larger in monkey than in rat 
(efflux ratios: 3.3 in monkey MDR1-expressing pcLLC.1 cells and 1.6 in rat 
Mdr1a-expressing pcLLC.1 cells) (34). One possibility would be the functional 
difference in the transport of etoposide and digoxin between the two species 
form of P-gp endogenously expressed in small intestine. Another possibility is 
that rapid basolateral efflux might mask the apical efflux mediated by P-gp. 
Indeed, the basolateral efflux (CLTB) of etoposide and digoxin was greater than 
the apical efflux (CLTA) in monkey intestine (Table 2). Therefore, it is possible 
that a transport system(s) is involved in basolateral efflux of etoposide and 
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digoxin in monkeys. MRP3 (ABCC3), which transports etoposide, is localized on 
the basolateral membrane (35). Further, it was reported that etoposide is an 
inhibitor of monkey MRP1, but a good substrate for human MRP1, and a poor 
substrate for murine Mrp1 (36). Accordingly, these MRPs are candidate 
transporters responsible for basolateral efflux of etoposide in monkey, and it will 
be necessary to investigate the expression and function of MRPs in monkey 
small intestine. 
In conclusion, we have demonstrated limited intestinal availability of 
etoposide and digoxin in both monkeys and rats. Kinetic analysis revealed that 
intestinal absorption of etoposide and digoxin is limited by apical uptake in 
monkeys, whereas back efflux to the luminal side mediated by P-gp limits the 
intestinal absorption in rats, but not in monkeys. Although the oral bioavailability 
of etoposide is similarly suppressed by limited intestinal permeability in both rats 
and monkeys, the intestinal absorption mechanism is thus different between the 
two species. Species difference of oral bioavailability between humans and 
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Plasma concentration profiles of etoposide, digoxin and theopylline in monkeys 
(A, B, C) and rats (D, E, F). Etoposide (A, D), digoxin (B, E) and theophylline (C, 
F) were intravenously (0.1 mg/kg, ○) and orally (1.0 mg/kg, ●) administered to 
monkeys and rats. Plasma concentration of each drug was analyzed by 
LC/MS/MS. Each point represents the mean ± S.D. of three determinations, 
except for digoxin administration to monkeys (n = 2). Pharmacokinetic 
parameters are listed in Table 1. 
 
Figure 2. Intestinal permeability of test compounds in monkeys (A) and rats (B). 
Permeability of etoposide (●), digoxin (or [3H]digoxin for rats) (■), theophylline 
(◆), FD-4 (◇) and inulin (○) in the upper, middle and lower small intestine was 
measured in an Ussing-type chamber. Etoposide and digoxin concentration in 
the donor side of the chamber was set at 30 µM. Theophylline concentration in 
the donor side of the chamber was set at 300 µM. FD-4 (or [14C]inulin in the 
[3H]digoxin transport study) concentration was 100 µM. Data are the mean ± 
S.E.M. of 3 - 4 determinations. CLabs and CLsec were obtained by dividing the 
amount of drugs that appeared in acceptor-side chamber by the area under the 
concentration curve in the donor-side chamber. e, i, d: Significant difference from 
CLabs for etoposide, inulin and digoxin, respectively (p < 0.05). 
 
Figure 3. Western blot analysis of intestinal P-gp in monkeys (A) and rats (B). 
Membrane proteins (20 µg/lane) prepared from upper, middle and lower small 
intestine were subjected to 10% SDS-PAGE. Relative band densities (% of 
upper small intestine) are shown in the lower panel. Each column is the mean ± 
S.E.M. of 3 - 4 animals.  
 
Figure 4. Schematic illustration of intestinal absorption mechanism for etoposide 
in monkey and rat. CLAT, CLTA, CLTB and CLBT mean membrane permeability (see 
text). The kinetic model shown represents that for all the segments of small 
intestine, but the higher permeability across the apical membranes (CLAT and 
CLTA) in rats is more obvious in the lower part of small intestine.
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Table 1. Pharmacokinetic parameters for etoposide, digoxin and theophylline in monkeys and 
ratsa)             
 Monkey  Etoposide  Digoxin  Theophylline  
  Parameter   0.1 mg/kg (iv) 1 mg/kg (oral)   0.1 mg/kg (iv) 1 mg/kg (oral)   0.1 mg/kg (iv) 1 mg/kg (oral)   
 Cmax (ng/mL)   –  137 ± 27   –  8.8     –  794 ± 75  
 Tmax (hr)   –  1.67 ± 0.58   –  0.75     –  6.67 ± 2.31  
 AUC0-last (ng·hr/mL)  1138 ± 233  1490 ± 427   260   158    1539 ± 44  14594 ± 796   
 CLtotal (mL/hr/kg)  90 ± 19  –   397    –   65 ± 2  –   
 Vdss (mL/kg)  164 ± 19  –   3519    –   577 ± 9  –   
 MRT (hr)  1.84 ± 0.18 6.10 ± 0.10  8.97   11.36    8.88 ± 0.31 10.26 ± 0.71  
 F (%)   –  12.9 ± 1.8   –  21.2     –  94.9 ± 6.2  
  MAT (hr)     –   4.26 ± 0.21     –   2.43         –   1.38 ± 0.77   
                                                
 Rat  Etoposide  Digoxin  Theophylline  
  Parameter   0.1 mg/kg (iv) 1 mg/kg (oral)   0.1 mg/kg (iv) 1 mg/kg (oral)   0.1 mg/kg (iv) 1 mg/kg (oral)   
 Cmax (ng/mL)   –  22.0 ± 0.5    –  58.4 ± 8.4   –  898 ± 168  
 Tmax (hr)   –  0.75 ± 0.43   –  2.67 ± 1.15   –  1.00 ± 0.00  
 AUC0-last (ng·hr/mL)  65.2 ± 6.2 90.4 ± 36.5  86.4 ± 13.2 457 ± 85  884 ± 63 7621 ± 1914  
 CLtotal (mL/hr/kg)  1542 ± 138  –   1177 ± 195  –   114 ± 8  –   
 Vdss (mL/kg)  849 ± 36  –   2722 ± 460  –   506 ± 24  –   
 MRT (hr)  0.55 ± 0.06 2.65 ± 0.94  2.31 ± 0.12 4.79 ± 0.78  4.45 ± 0.13 4.98 ± 0.21  
 F (%)   –  13.9 ± 5.8   –  52.8 ± 12.8   –  86.2 ± 22.5  
  MAT (hr)     –   2.1 ± 0.94     –   2.48 ± 0.79     –   0.53  ± 0.25   




Table 2. Microscopic parameters representing membrane permeabilities of etoposide, digoxin, and theophylline in monkey and rat 
small intestinea) Animal Test 
compound 
Segment of Concn.b) CLATc) CLTAd) CLTBe) CLBTf)     
    small 
intestine 
(µM) (10-6 cm/sec) (10-6 cm/sec) (10-6 cm/sec) (10-6 cm/sec)     
Monkey Etoposide Upper 30 0.373  ± 0.091  0.180h  ± 0.044  2.77  ± 0.54  1.46  ± 0.25     
  Middle 30 0.219g  ± 0.098  0.080h  ± 0.080  1.26  ± 0.41  0.550  ± 0.213    
  Lower 30 0.670g 
g g 
± 0.118  1.62  ± 0.68  2.01  ± 0.08  1.98  ± 0.64     
 Digoxin Upper 30 0.181g ± 0.085  0.342 ± 0.276  1.06  ± 0.43  0.404  ± 0.170    
  Middle 30 0.363g ± 0.157  0.198 ± 0.105  1.80  ± 0.95  0.505  ± 0.333    
  Lower 30 0.873g ± 0.136  1.59h ± 0.38  3.92  ± 0.30  1.68  ± 0.19     
 Theophylline Upper 300 16.6  ± 2.5  17.8  ± 0.8  37.6  ± 12.2  31.2  ± 7.7     
  Middle 300 11.1g ± 0.7  11.9h ± 2.5  21.9  ± 2.6  15.9  ± 2.7     
    Lower 300 28.9  ± 6.1  32.9  ± 7.8  32.3  ± 6.1  25.9  ± 5.8      
Rat Etoposide Upper 30 1.87  ± 0.59  6.37  ± 2.94  3.82  ± 0.33  2.30  ± 0.72     
  Middle 30 7.83  ± 1.52  26.9h ± 6.0  5.09  ± 1.15  6.68  ± 0.70     
  Lower 30 11.7  ± 2.5  44.2h ± 12.8  6.97  ± 2.50  9.56  ± 1.80     
 Digoxin Upper 30 3.65  ± 0.49  41.1  ± 4.5  36.0  ± 5.7  4.84  ± 0.78     
  Middle 30 4.58  ± 0.82  43.2  ± 9.8  38.4  ± 7.2  6.46  ± 1.20     
  Lower 30 9.64  ± 1.32  131h ± 26  34.4  ± 3.7  9.02  ± 0.97     
 Theophylline Upper 300 20.7  ± 2.1  58.2  ± 4.6  53.2  ± 1.7  15.1  ± 1.6     
  Middle 300 30.8  ± 5.6  90.4  ± 30.5  113  ± 25  24.2  ± 5.8     
    Lower 300 45.3  ± 6.2  167  ± 33  154  ± 10  33.5  ± 4.9      
a) Each value represents the mean ± S.E.M. of 3-4 determinations.    
b) Concentration of the test compound in the donor-side chamber.     
c) Membrane permeability across apical membrane from Apical-side buffer into Tissue (AT)    
d) Membrane permeability across apical membrane from Tissue into Apical-side buffer (TA)    
e) Membrane permeability across basal membrane from Tissue into Basal-side buffer (TB)    
f) Membrane permeability across basal membrane from Basal-side buffer into Tissue (BT)    
g) Significantly different (p < 0.05) from the corresponding values obtained in rats by students’ t-test.    
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